Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study

BACKGROUND: Rilpivirine is safe and effective in HIV-naïve patients with low baseline HIV-RNA or in switch strategy. It offers the advantages of few drug-drug interactions and a favourable toxicity profile. We aimed to determine the reasons for prescribing the rilpivirine (RPV)/tenofovir disoproxil...

Descripción completa

Detalles Bibliográficos
Autores principales: Sculier, Delphine, Gayet-Ageron, Angèle, Battegay, Manuel, Cavassini, Matthias, Fehr, Jan, Hirzel, Cedric, Schmid, Patrick, Bernasconi, Enos, Calmy, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500925/
https://www.ncbi.nlm.nih.gov/pubmed/28683720
http://dx.doi.org/10.1186/s12879-017-2579-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500925/
https://www.ncbi.nlm.nih.gov/pubmed/28683720
http://dx.doi.org/10.1186/s12879-017-2579-2

Ejemplares similares